The purpose of this study is to determine whether early intervention with subcutaneous (s.c.)
secukinumab 300 mg in patients with new-onset moderate to severe plaque psoriasis may lead to
prolonged symptom free periods by preventing reactivation of old lesions or ultimately
totally hindering the occurrence of new lesions, i.e., changing the natural course of the
disease (Main Study).